Optima to host post-conference workshop at Lyophilization USA

SMi Group23 - 24 October 2019, Boston, USA.
Delegates for the 5th Annual Lyophilization USA conference, taking place in Boston, will have the opportunity to attend the half-day post-conference workshop titled "Current and Future Freeze-Drying Technologies and Methods" led by Dena Flamm and Alexander Tambovzev on October 25th 2019.

Overview of the workshop

Freeze dried products are well established in the market with an increasing trend in aseptically produced lyophilized products, including peptides and proteins. This workshop will give delegates an introduction into the Physics and Thermodynamics of Freeze-Drying; including both presentation of topics and an open discussion within the group. The session will support a better understanding of the Freeze-Drying process with the different methods available in the marketas well as discuss an alternative Freeze-Drying process for consideration.

Benefits of Attending

Delegates will have the opportunity to engage in an in-depth discussion with industry experts from Optima on the latest technological developments in the Lyophilization industry. They will also gain a better understanding of the most up to date freeze-drying technology available on the market, as well as what the future of this field looks like.

This workshop will enhance delegate's knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze-drying technologies including spray drying, spin freeze-drying and microwave drying.

The brochure with the full conference program and workshop information is available to download online at http://www.lyophilisation-usa.com/PR3

Workshop Leader Overview

Dena Flamm is a Business Development Manager for OptimaMachinery Corporation. She is responsible for freeze dryer development in the North American market and has over 17 years of experience in the pharmaceutical industry. Studies include, an MBA in International Management from the University of St. Thomas with an undergraduate degree in Business and Physics.

Alexander Tambovzev is a Project Engineering and Development Group Leader at Optima Pharma, Germany. The area of his responsibility is leading the project engineering of the freeze dryers as well as the R&D effort in the freeze dryer technology. In 2008, Alexander received a Ph.D. in refrigeration technology from the Technical University of Dresden with a focus on the modelling of dynamic processes. He has worked in the research and development area of refrigeration systems for commercial and industrial applications.

An early bird saving of $200 is available for bookings placed before the 30th August. Registrations can be made online at http://www.lyophilisation-usa.com/PR3

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Pharmacist-led interventions may help prevent card…

With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the Brit...